Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma.
immune checkpoint inhibitors
liver cancer
recurrence
tumor microenvironment
Journal
Journal of hepatocellular carcinoma
ISSN: 2253-5969
Titre abrégé: J Hepatocell Carcinoma
Pays: New Zealand
ID NLM: 101674775
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
06
2023
accepted:
24
10
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Systemic treatment for advanced hepatocellular carcinoma (HCC) has been revolutionized over the last few years following the approval of immune checkpoint inhibitors (ICI). Despite the promising survival extension seen with ICI combination regimens, responses are not universally seen and the optimal partner for programmed cell death 1 pathway inhibitors remains to be identified. Even fewer encouraging results have been demonstrated with ICI used for monotherapy. Several mechanisms of resistance have been described so far, involving characteristics of cancer cells (intrinsic mechanisms) and of the surrounding tumor microenvironment (extrinsic mechanisms). Factors related to therapy may also contribute to the development of resistance. Increasing research efforts are being dedicated to the discovery of novel approaches and targets to overcome resistance, some of which may be introduced into clinic in the future. Herein we describe a selection of resistance mechanisms that have been involved in impairing response to ICI and propose potential therapeutic approaches to overcome resistance.
Identifiants
pubmed: 37941812
doi: 10.2147/JHC.S291553
pii: 291553
pmc: PMC10629523
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1955-1971Informations de copyright
© 2023 Manfredi et al.
Déclaration de conflit d'intérêts
CC received speaker fees from Eisai, MSD, and Ipsen. BS received travel support from AbbVie, AstraZeneca, Ipsen, and Gilead. JK received travel grant funds from Boehringer Ingelheim. MP received speaker honoraria from Bayer, BMS, Eisai, Lilly, MSD, and Roche; he is a consultant for AstraZeneca, Bayer, BMS, Eisai, Ipsen, Lilly, MSD, and Roche; he received travel support from Bayer, BMS, and Roche. GC has served as a consultant or on advisory boards for Bayer, Eisai, Ipsen, MSD, AstraZeneca, and Roche. AD received educational support for congress attendance and consultancy fees from Roche. DJP received lecture fees from ViiV Healthcare and Bayer Healthcare; travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and Astra Zeneca; and received research funding (to institution) from MSD and BMS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Références
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Am J Pathol. 2015 Mar;185(3):820-33
pubmed: 25549835
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5744-9
pubmed: 9159144
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Front Immunol. 2022 Jul 26;13:956090
pubmed: 35958563
Cell Rep. 2020 Jan 14;30(2):481-496.e6
pubmed: 31940491
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Ann Transl Med. 2021 Jun;9(12):1034
pubmed: 34277834
Ann Intern Med. 2004 Jul 6;141(1):9-15
pubmed: 15238365
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Int J Biol Sci. 2022 Mar 28;18(7):2775-2794
pubmed: 35541908
Eur J Cancer. 2001 Sep;37(13):1709-18
pubmed: 11527700
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Cancer Discov. 2017 Dec;7(12):1420-1435
pubmed: 29025772
Oncogene. 2007 Apr 2;26(15):2166-76
pubmed: 17401425
Lancet Oncol. 2022 Jan;23(1):77-90
pubmed: 34914889
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231163677
pubmed: 36938618
Oncotarget. 2017 May 29;8(37):61425-61439
pubmed: 28977875
Am J Respir Crit Care Med. 2008 Apr 1;177(7):763-70
pubmed: 18096709
J Hepatol. 2022 Apr;76(4):862-873
pubmed: 34902530
Gastroenterology. 2008 May;134(6):1655-69
pubmed: 18471545
Cell. 2020 Oct 15;183(2):347-362.e24
pubmed: 33064988
Cancer Sci. 2012 Jun;103(6):984-92
pubmed: 22417086
J Clin Invest. 2016 Aug 1;126(8):3036-52
pubmed: 27427982
Cancer Cell. 2021 Jun 14;39(6):845-865.e7
pubmed: 34019806
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Biochem Biophys Res Commun. 1993 Jun 15;193(2):681-7
pubmed: 8390249
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827906
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Front Oncol. 2021 Feb 19;10:610513
pubmed: 33680932
Front Oncol. 2022 Sep 02;12:958720
pubmed: 36119533
J Hepatocell Carcinoma. 2018 Jun 27;5:61-73
pubmed: 29984212
Oncogenesis. 2016 Feb 22;5:e198
pubmed: 26900950
Hepatology. 2019 Jul;70(1):198-214
pubmed: 30810243
FASEB J. 1996 May;10(7):769-76
pubmed: 8635694
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Front Immunol. 2018 Mar 01;9:414
pubmed: 29545811
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Immunol Lett. 2013 Feb;150(1-2):116-22
pubmed: 23261718
J Cancer Res Clin Oncol. 2023 Apr;149(4):1425-1441
pubmed: 35482077
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929051
Curr Opin Immunol. 2009 Apr;21(2):215-23
pubmed: 19327974
Gut. 2023 Jan;72(1):141-152
pubmed: 34933916
Cell Mol Gastroenterol Hepatol. 2021;12(2):443-464
pubmed: 33781741
Gut. 2022 Jun;71(6):1176-1191
pubmed: 34253573
Biology (Basel). 2023 Jan 30;12(2):
pubmed: 36829496
Int J Mol Sci. 2023 Feb 08;24(4):
pubmed: 36834851
Int Immunopharmacol. 2022 Nov;112:109244
pubmed: 36126410
World J Hepatol. 2015 Aug 18;7(17):2080-90
pubmed: 26301050
Nat Immunol. 2011 Dec 11;13(2):188-95
pubmed: 22157630
Int J Mol Sci. 2021 May 24;22(11):
pubmed: 34073989
J Immunol. 2000 May 15;164(10):4991-5
pubmed: 10799849
World J Gastroenterol. 2009 Feb 7;15(5):513-20
pubmed: 19195051
J Hepatocell Carcinoma. 2022 Oct 26;9:1109-1125
pubmed: 36320666
JHEP Rep. 2023 Feb 18;5(5):100702
pubmed: 37025943
J Clin Oncol. 2023 Mar 20;41(9):1747-1757
pubmed: 36512738
Cancer Cell. 2021 Feb 8;39(2):154-173
pubmed: 33125859
Semin Cancer Biol. 2011 Feb;21(1):35-43
pubmed: 20946957
Cancer Immunol Res. 2015 Dec;3(12):1344-55
pubmed: 26253731
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Eur J Immunol. 2011 Apr;41(4):902-15
pubmed: 21416464
JAMA Oncol. 2022 Dec 1;8(12):1825-1829
pubmed: 36264560
PLoS One. 2010 Mar 24;5(3):e9836
pubmed: 20352091
Trends Mol Med. 2019 Nov;25(11):1010-1023
pubmed: 31353124
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Genes Dev. 2016 May 1;30(9):1002-19
pubmed: 27151975
Front Oncol. 2023 Feb 17;13:1060112
pubmed: 36874131
Gut. 2016 May;65(5):749-56
pubmed: 26719299
Front Oncol. 2022 Aug 16;12:944722
pubmed: 36046045
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
Eur J Cancer. 2022 Nov;175:204-213
pubmed: 36148739
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Cancer Discov. 2016 Dec;6(12):1366-1381
pubmed: 27683557
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Int J Mol Sci. 2019 Apr 07;20(7):
pubmed: 30959975
Int J Mol Sci. 2017 Feb 14;18(2):
pubmed: 28216578
Cytokine Growth Factor Rev. 2017 Aug;36:125-129
pubmed: 28688773
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
J Exp Med. 2011 Feb 14;208(2):395-407
pubmed: 21300912
Cancers (Basel). 2023 Apr 15;15(8):
pubmed: 37190239
J Clin Invest. 2022 Feb 15;132(4):
pubmed: 35166233
Gut. 2023 Jan;72(1):129-140
pubmed: 35197323
Clin Lab Med. 2014 Dec;34(4):771-85
pubmed: 25439276
Front Oncol. 2022 Jul 08;12:927440
pubmed: 35875168
Sci Transl Med. 2018 Oct 24;10(464):
pubmed: 30355800
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
Lancet Oncol. 2022 Aug;23(8):995-1008
pubmed: 35798016
Hepat Oncol. 2021 Aug 03;8(4):HEP39
pubmed: 34765106
Front Oncol. 2022 Feb 22;12:810269
pubmed: 35273912
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126
pubmed: 30373752
Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004
pubmed: 27162338
Nature. 2001 Apr 26;410(6832):1103-7
pubmed: 11323674
Nat Rev Immunol. 2023 Sep;23(9):580-594
pubmed: 36750615
World J Gastroenterol. 2016 Jan 7;22(1):275-83
pubmed: 26755876
J Hepatol. 2022 Dec;77(6):1598-1606
pubmed: 36208844
Int J Mol Sci. 2023 Feb 15;24(4):
pubmed: 36835352
Int J Mol Sci. 2022 Feb 11;23(4):
pubmed: 35216137
Oncogene. 2017 Feb 23;36(8):1090-1101
pubmed: 27593937
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Hepatology. 2010 Apr;51(4):1274-83
pubmed: 20112254
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Int J Mol Sci. 2022 Sep 18;23(18):
pubmed: 36142818
Am J Transl Res. 2020 Jul 15;12(7):3212-3224
pubmed: 32774695
Cancer Treat Res Commun. 2021;27:100328
pubmed: 33549983
J Hepatol. 2023 Apr;78(4):770-782
pubmed: 36708811
Antibodies (Basel). 2019 Mar 05;8(1):
pubmed: 31544827
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
Gastroenterology. 2017 Sep;153(3):812-826
pubmed: 28624577
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
JAMA Oncol. 2020 Nov 01;6(11):e204564
pubmed: 33001135
J Clin Invest. 2013 May;123(5):1902-10
pubmed: 23635788
J Immunol. 2009 Mar 1;182(5):3047-54
pubmed: 19234201
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172
pubmed: 34764464
Front Immunol. 2020 Aug 18;11:1951
pubmed: 33013848
World J Hepatol. 2023 Feb 27;15(2):129-150
pubmed: 36926237
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):166-79
pubmed: 20036813
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Semin Cancer Biol. 2014 Apr;25:69-77
pubmed: 24406209
J Gastroenterol Hepatol. 1999 Jul;14(7):618-33
pubmed: 10440206
Annu Rev Immunol. 2020 Apr 26;38:23-48
pubmed: 32340570
Biomedicines. 2022 Aug 12;10(8):
pubmed: 36009506
World J Hepatol. 2021 Sep 27;13(9):979-1002
pubmed: 34630870
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Mol Cancer. 2021 Oct 11;20(1):131
pubmed: 34635121
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Front Immunol. 2021 Feb 02;11:622509
pubmed: 33633741
Cancer Lett. 2019 May 28;450:132-143
pubmed: 30849480
JAMA Oncol. 2019 Dec 1;5(12):1774-1778
pubmed: 31513236
Biochim Biophys Acta. 2000 Jun 21;1492(1):31-44
pubmed: 11004478
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33154150
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8847-51
pubmed: 9671767
J Clin Invest. 2018 Nov 1;128(11):4870-4883
pubmed: 30137027
Cancer Res. 2012 Aug 15;72(16):3977-86
pubmed: 22719066
Front Oncol. 2023 May 01;13:1172314
pubmed: 37197415
J Immunol. 2013 Mar 1;190(5):2009-16
pubmed: 23359509
Clin Cancer Res. 2014 Dec 15;20(24):6418-28
pubmed: 25320357
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
J Hematol Oncol. 2022 Mar 18;15(1):28
pubmed: 35303904
Gene Ther. 2010 Sep;17(9):1105-16
pubmed: 20428216
Cell Res. 2020 Aug;30(8):660-669
pubmed: 32467592
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Front Pharmacol. 2023 Mar 14;14:1113378
pubmed: 37007004
J Cell Sci. 2020 Mar 6;133(5):
pubmed: 32144194
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Int J Mol Sci. 2019 Oct 13;20(20):
pubmed: 31614930
J Immunol. 2011 Feb 1;186(3):1338-42
pubmed: 21199897
J Rheumatol. 2012 May;39(5):933-8
pubmed: 22422501
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cell Death Dis. 2021 Mar 11;12(3):260
pubmed: 33707417
Mod Pathol. 2005 Dec;18(12):1591-8
pubmed: 15920546
J Immunother Cancer. 2019 Apr 15;7(1):105
pubmed: 30992085
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Mol Biol Rep. 2022 Aug;49(8):7911-7919
pubmed: 35776395
Oncologist. 2016 Oct;21(10):1260-1268
pubmed: 27440064
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
J Thorac Oncol. 2022 Jun;17(6):739-741
pubmed: 35623673
Cell. 2017 Feb 23;168(5):928-943.e11
pubmed: 28215708
PLoS One. 2013 Sep 02;8(9):e73312
pubmed: 24023859
J Immunol. 2015 Apr 15;194(8):3873-82
pubmed: 25780040
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
J Hepatol. 2022 Aug;77(2):397-409
pubmed: 35367533
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Clin Cancer Res. 2020 Feb 15;26(4):787-792
pubmed: 31757876
Nat Commun. 2016 Oct 20;7:13151
pubmed: 27762264
Cell Death Dis. 2022 May 20;13(5):478
pubmed: 35589690
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
World J Gastroenterol. 2004 Sep 15;10(18):2744-6
pubmed: 15309732
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
JHEP Rep. 2023 Mar 30;5(6):100747
pubmed: 37197442
Oncogene. 2020 Apr;39(18):3620-3637
pubmed: 32157213
Eur J Immunol. 2003 Apr;33(4):970-9
pubmed: 12672063
Inflamm Bowel Dis. 2015 May;21(5):963-72
pubmed: 25738379
Lancet Oncol. 2022 Apr;23(4):521-530
pubmed: 35255263
Cancer Lett. 2015 Oct 10;367(1):1-11
pubmed: 26170167
J Immunother Cancer. 2019 Nov 29;7(1):331
pubmed: 31783783
J Hepatol. 2013 Sep;59(3):528-35
pubmed: 23665041
Dig Liver Dis. 2023 Apr;55(4):464-470
pubmed: 36804053
Eur J Gastroenterol Hepatol. 2006 Apr;18(4):375-9
pubmed: 16538108
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Hepatology. 2004 Dec;40(6):1312-21
pubmed: 15565659